PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28514601
OWN - NLM
STAT- MEDLINE
DA  - 20170517
DCOM- 20170522
LR  - 20170525
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
VI  - 376
IP  - 20
DP  - 2017 May 18
TI  - Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
PG  - 1921-1932
LID - 10.1056/NEJMoa1702079 [doi]
AB  - BACKGROUND: Eosinophilic granulomatosis with polyangiitis is an eosinophilic
      vasculitis. Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood
      eosinophil counts and may have value in the treatment of eosinophilic
      granulomatosis with polyangiitis. METHODS: In this multicenter, double-blind,
      parallel-group, phase 3 trial, we randomly assigned participants with relapsing
      or refractory eosinophilic granulomatosis with polyangiitis who had received
      treatment for at least 4 weeks and were taking a stable prednisolone or
      prednisone dose to receive 300 mg of mepolizumab or placebo, administered
      subcutaneously every 4 weeks, plus standard care, for 52 weeks. The two primary
      end points were the accrued weeks of remission over a 52-week period, according
      to categorical quantification, and the proportion of participants in remission at
      both week 36 and week 48. Secondary end points included the time to first relapse
      and the average daily glucocorticoid dose (during weeks 48 through 52). The
      annualized relapse rate and safety were assessed. RESULTS: A total of 136
      participants underwent randomization, with 68 participants assigned to receive
      mepolizumab and 68 to receive placebo. Mepolizumab treatment led to significantly
      more accrued weeks of remission than placebo (28% vs. 3% of the participants had 
      >/=24 weeks of accrued remission; odds ratio, 5.91; 95% confidence interval [CI],
      2.68 to 13.03; P<0.001) and a higher percentage of participants in remission at
      both week 36 and week 48 (32% vs. 3%; odds ratio, 16.74; 95% CI, 3.61 to 77.56;
      P<0.001). Remission did not occur in 47% of the participants in the mepolizumab
      group versus 81% of those in the placebo group. The annualized relapse rate was
      1.14 in the mepolizumab group, as compared with 2.27 in the placebo group (rate
      ratio, 0.50; 95% CI, 0.36 to 0.70; P<0.001). A total of 44% of the participants
      in the mepolizumab group, as compared with 7% of those in the placebo group, had 
      an average daily dose of prednisolone or prednisone of 4.0 mg or less per day
      during weeks 48 through 52 (odds ratio, 0.20; 95% CI, 0.09 to 0.41; P<0.001). The
      safety profile of mepolizumab was similar to that observed in previous studies.
      CONCLUSIONS: In participants with eosinophilic granulomatosis with polyangiitis, 
      mepolizumab resulted in significantly more weeks in remission and a higher
      proportion of participants in remission than did placebo, thus allowing for
      reduced glucocorticoid use. Even so, only approximately half the participants
      treated with mepolizumab had protocol-defined remission. (Funded by
      GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases;
      ClinicalTrials.gov number, NCT02020889 .).
FAU - Wechsler, Michael E
AU  - Wechsler ME
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Akuthota, Praveen
AU  - Akuthota P
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Jayne, David
AU  - Jayne D
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Khoury, Paneez
AU  - Khoury P
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Klion, Amy
AU  - Klion A
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Langford, Carol A
AU  - Langford CA
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Merkel, Peter A
AU  - Merkel PA
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Moosig, Frank
AU  - Moosig F
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Specks, Ulrich
AU  - Specks U
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Cid, Maria C
AU  - Cid MC
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Luqmani, Raashid
AU  - Luqmani R
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Brown, Judith
AU  - Brown J
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Mallett, Stephen
AU  - Mallett S
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Philipson, Richard
AU  - Philipson R
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Yancey, Steve W
AU  - Yancey SW
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Steinfeld, Jonathan
AU  - Steinfeld J
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Weller, Peter F
AU  - Weller PF
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
FAU - Gleich, Gerald J
AU  - Gleich GJ
AD  - From the Department of Medicine, National Jewish Health, Denver (M.E.W.); the
      Division of Pulmonary, Critical Care, and Sleep Medicine, University of
      California San Diego, La Jolla (P.A.); Beth Israel Deaconess Medical Center,
      Boston (P.A., P.F.W.); the Department of Medicine, University of Cambridge,
      Cambridge (D.J.), the Department of Orthopaedics, Rheumatology, and
      Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford
      (R.L.), Research and Development, Immuno-Inflammation Therapy Area Unit (J.B.),
      and Research and Development, Statistics, Programming, and Data Standards (S.M.),
      GlaxoSmithKline, Uxbridge, and Trizell, Oxford (R.P.) - all in the United
      Kingdom; the Human Eosinophil Section, Laboratory of Parasitic Diseases, National
      Institute of Allergy and Infectious Diseases, National Institutes of Health,
      Bethesda, MD (P.K., A.K.); the Center for Vasculitis Care and Research, Cleveland
      Clinic, Cleveland (C.A.L.); the Division of Rheumatology and the Department of
      Biostatistics and Clinical Epidemiology, University of Pennsylvania (P.A.M.), and
      the Respiratory Therapy Area Unit and Flexible Discovery Unit, GlaxoSmithKline
      (J.S.), Philadelphia; Rheumazentrum, Schleswig-Holstein Mitte, Neumunster,
      Germany (F.M.); the Division of Pulmonary and Critical Care Medicine, Mayo
      Clinic, Rochester, MN (U.S.); the Vasculitis Research Unit, Department of
      Autoimmune Diseases, Hospital Clinic University of Barcelona, Institut
      d'Investigacions Biomediques August Pi i Sunyer, Barcelona (M.C.C.); the
      Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC
      (S.W.Y.); and the Departments of Dermatology and Medicine, University of Utah
      School of Medicine, Salt Lake City (G.J.G.).
CN  - EGPA Mepolizumab Study Team
LA  - eng
SI  - ClinicalTrials.gov/NCT02020889
GR  - U01 AI097073/AI/NIAID NIH HHS/United States
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunologic Factors)
RN  - 0 (mepolizumab)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Churg-Strauss Syndrome/*drug therapy/immunology
MH  - Disease-Free Survival
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Eosinophils
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunologic Factors/adverse effects/*therapeutic use
MH  - Injections, Subcutaneous/adverse effects
MH  - Intention to Treat Analysis
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Recurrence
MH  - Remission Induction
IR  - Baldini C
FIR - Baldini, Chiara
IR  - Beach DM
FIR - Beach, Douglas M
IR  - Bochner B
FIR - Bochner, Bruce
IR  - Bourdin A
FIR - Bourdin, Arnaud
IR  - Chanez P
FIR - Chanez, Pascal
IR  - Chauhan A
FIR - Chauhan, Anoop
IR  - Cottin V
FIR - Cottin, Vincent
IR  - Denson J
FIR - Denson, Joshua
IR  - Dollin Y
FIR - Dollin, Yeshai
IR  - Dunn RM
FIR - Dunn, Ryan M
IR  - Dunogue B
FIR - Dunogue, Bertrand
IR  - Espigol-Frigole G
FIR - Espigol-Frigole, Georgina
IR  - Fischer A
FIR - Fischer, Aryeh
IR  - Hajj-Ali R
FIR - Hajj-Ali, Rula
IR  - Hellmich B
FIR - Hellmich, Berhnard
IR  - Rodriguez JH
FIR - Rodriguez, Jose Hernandez
IR  - Holle J
FIR - Holle, Julia
IR  - Iking-Konert C
FIR - Iking-Konert, Christof
IR  - Ishii T
FIR - Ishii, Tomonori
IR  - Kahn JE
FIR - Kahn, Jean-Emmanuel
IR  - Kern P
FIR - Kern, Peter
IR  - Khalidi N
FIR - Khalidi, Nader
IR  - Koening CL
FIR - Koening, Curry L
IR  - Matucci A
FIR - Matucci, Andrea
IR  - Monach P
FIR - Monach, Paul
IR  - Morehouse L
FIR - Morehouse, Lindsay
IR  - Murphy R
FIR - Murphy, Ryann
IR  - Neumann T
FIR - Neumann, Thomas
IR  - Pagnoux C
FIR - Pagnoux, Christian
IR  - Pastorello E
FIR - Pastorello, Elide
IR  - Prieto-Gonzalez S
FIR - Prieto-Gonzalez, Sergio
IR  - Puechal X
FIR - Puechal, Xavier
IR  - Raby BA
FIR - Raby, Benjamin A
IR  - Roufosse F
FIR - Roufosse, Florence
IR  - Sabbadini MG
FIR - Sabbadini, Maria Grazia
IR  - Schirmer J
FIR - Schirmer, Jan
IR  - Sreih AG
FIR - Sreih, Antoine G
IR  - Taniguchi M
FIR - Taniguchi, Masami
IR  - Voll R
FIR - Voll, Reinhard
IR  - Wardlaw A
FIR - Wardlaw, Andrew
EDAT- 2017/05/18 06:00
MHDA- 2017/05/23 06:00
CRDT- 2017/05/18 06:00
AID - 10.1056/NEJMoa1702079 [doi]
PST - ppublish
SO  - N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>